These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6800179)

  • 1. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet function and its disorders--some aspects from the arachidonic acid metabolism.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1984 Dec; 47(8):1542-55. PubMed ID: 6442514
    [No Abstract]   [Full Text] [Related]  

  • 4. [Defects in the prostaglandin system. VIII. A pathologic thrombocyte population in myeloproliferative syndrome, which forms no thromboxane from exogenous arachidonic acid].
    Sinzinger H; Gisslinger H; Linkesch W; Ludwig H; Flener R; Peskar BA
    Wien Klin Wochenschr; 1988 Nov; 100(21):715-8. PubMed ID: 3149432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders.
    Takayama H; Okuma M; Kanaji K; Sugiyama T; Sensaki S; Uchino H
    Prostaglandins Leukot Med; 1983 Nov; 12(3):261-72. PubMed ID: 6318227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
    Berild D; Hasselbalch H; Knudsen JB
    Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of the morphology and function of the thrombocytes in myeloproliferative diseases].
    Petrov MN; Vashkinel' VK
    Probl Gematol Pereliv Krovi; 1977 May; 22(5):18-23. PubMed ID: 267283
    [No Abstract]   [Full Text] [Related]  

  • 9. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
    Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
    Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 13. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
    Viero P; Cortelazzo S; Bassan R; Barbui T
    Thromb Haemost; 1982 Oct; 48(2):125-6. PubMed ID: 6184841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 17. Stainable blood platelet glycogen in various conditions.
    Hermanský F; Hrodek O; Matousová O; Cieslar P
    Acta Univ Carol Med Monogr; 1972; 53():165-71. PubMed ID: 4598518
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnostic considerations in myelofibrosis].
    Dieska D; Gocárová K; Horváth A; Vahancík A
    Bratisl Lek Listy; 1970 Nov; 54(5):637-42. PubMed ID: 5276096
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
    Moliterno AR; Hankins WD; Spivak JL
    N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.